Takeaway
- Adjuvant nivolumab is effective and well-tolerated in patients who have undergone radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
Why this matters
- These initial findings from the phase 3 CheckMate 274 trial support nivolumab monotherapy as a new standard of care in the adjuvant setting for patients with high-risk MIUC after...
